SRRK Key Statistics, Chart & Performance
The current stock price of SRRK is 44.23 USD. In the past month the price decreased by -2.25%. In the past year, price increased by 9.24%.
SRRK Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.7 | 412.54B | ||
| AMGN | AMGEN INC | 15.62 | 183.97B | ||
| GILD | GILEAD SCIENCES INC | 15.18 | 154.28B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 27.89 | 122.84B | ||
| REGN | REGENERON PHARMACEUTICALS | 18.05 | 85.37B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 828.43 | 55.82B | ||
| INSM | INSMED INC | N/A | 37.54B | ||
| NTRA | NATERA INC | N/A | 35.11B | ||
| BIIB | BIOGEN INC | 11.17 | 27.42B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.09 | 21.69B | ||
| INCY | INCYTE CORP | 17.22 | 21.71B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.29B |
Related stock screener links
About SRRK
Company Profile
Scholar Rock Holding Corp. is a biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 196 full-time employees. The company went IPO on 2018-05-24. The company is focused on advancing treatments for neuromuscular diseases, cardiometabolic disorders, and other serious diseases. Its transforming growth factor beta (TGFb) superfamily biology, its novel molecular mechanisms of growth factor activation enabled it to develop a proprietary platform for the discovery and development of monoclonal antibodies that locally and selectively target the precursor, or latent, forms of growth factors. Its product candidate, apitegromab, is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Apitegromab is being developed as a potential first muscle-targeted therapy for the treatment of SMA. Its products include SRK-439, SRK-181, SRK-373 and SRK-256. SRK-181 is a selective inhibitor of the activation of latent TGFb1, is being developed for the treatment of cancers.
Company Info
SCHOLAR ROCK HOLDING CORP
301 Binney Street, 3rd Floor
Cambridge MASSACHUSETTS 02142 US
CEO: Stuart A. Kingsley
Employees: 196
Phone: 18572593860
SCHOLAR ROCK HOLDING CORP / SRRK FAQ
What does SRRK do?
Scholar Rock Holding Corp. is a biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 196 full-time employees. The company went IPO on 2018-05-24. The company is focused on advancing treatments for neuromuscular diseases, cardiometabolic disorders, and other serious diseases. Its transforming growth factor beta (TGFb) superfamily biology, its novel molecular mechanisms of growth factor activation enabled it to develop a proprietary platform for the discovery and development of monoclonal antibodies that locally and selectively target the precursor, or latent, forms of growth factors. Its product candidate, apitegromab, is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Apitegromab is being developed as a potential first muscle-targeted therapy for the treatment of SMA. Its products include SRK-439, SRK-181, SRK-373 and SRK-256. SRK-181 is a selective inhibitor of the activation of latent TGFb1, is being developed for the treatment of cancers.
What is the current price of SRRK stock?
The current stock price of SRRK is 44.23 USD. The price increased by 7.07% in the last trading session.
Does SCHOLAR ROCK HOLDING CORP pay dividends?
SRRK does not pay a dividend.
How is the ChartMill rating for SCHOLAR ROCK HOLDING CORP?
SRRK has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
On which exchange is SRRK stock listed?
SRRK stock is listed on the Nasdaq exchange.
Should I buy SRRK stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on SRRK.
SRRK Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to SRRK. When comparing the yearly performance of all stocks, SRRK turns out to be only a medium performer in the overall market: it outperformed 65.24% of all stocks.
SRRK Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to SRRK. The financial health of SRRK is average, but there are quite some concerns on its profitability.
SRRK Financial Highlights
Over the last trailing twelve months SRRK reported a non-GAAP Earnings per Share(EPS) of -3.16. The EPS decreased by -34.47% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -85.84% | ||
| ROE | -144.26% | ||
| Debt/Equity | 0.41 |
SRRK Forecast & Estimates
20 analysts have analysed SRRK and the average price target is 48.88 USD. This implies a price increase of 10.5% is expected in the next year compared to the current price of 44.23.